Wednesday, 14 December 2022

THE 1ST BOAO INTERNATIONAL CONFERENCE ON REAL WORLD STUDIES OF MEDICAL PRODUCTS HELD IN HAINAN

HAIKOU, China, Dec. 12, 2022 /Xinhua-AsiaNet/--

On December 8, the first Boao International Conference on Real World Studies of Medical Products was held in Hainan Province, with the theme of "Real World Data Studies and Innovative Development and Supervision of Medical Products".

Hainan Boao Lecheng International Medical Tourism Pilot Zone, as the unique "Medical Special Zone" in China, is the only pilot region that makes active use of real data application. In recent years, it has grown into the most important channel for international innovative medical devices to enter China, initially achieving the synchronization with the international advanced level in the three areas of medical technology, equipment and medicines.

Feng Fei, Governor of Hainan Province, said in his speech that since 2019 Lecheng Pilot Zone had established in-depth cooperation with more than 80 medical device enterprises in 16 countries and regions. More than 270 kinds of medical products that are in urgent clinical need have been introduced from overseas. A total of nine kinds of products have been approved for listing in China through the use of real-world data from Lecheng to supplement clinical evaluation. "I sincerely hope that experts, scholars, guests and friends attending the meeting will have in-depth discussions and exchanges to promote Lecheng Pilot Zone to become a new highland for real world study and a new engine for the development of China's pharmaceutical industry," Feng Fei said. 

http://mrem.bernama.com/viewsm.php?idm=44986

TESSA THERAPEUTICS ANNOUNCES UPDATED SAFETY, EFFICACY AND BIOMARKER DATA FROM PHASE 2 TRIAL OF AUTOLOGOUS CD30.CAR-T THERAPY (TT11) IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete response rate from 15 heavily pre-treated patients dosed with TT11

Research presented in an oral podium presentation during the 2022 ASH Annual Meeting demonstrates potential of circulating tumor DNA (ctDNA) as a biomarker to predict outcomes of patients with r/r classical Hodgkin lymphoma (cHL) treated with CD30.CAR-T therapy

SINGAPORE, Dec 13 (Bernama-GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced updated clinical data from the pilot stage of the ongoing Phase 2 CHARIOT trial (NCT04268706) of TT11, the Company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy, were presented in a poster and oral podium presentation at the 64rd Annual Meeting of the American Society of Hematology (ASH). The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL). Moreover, research identified circulating tumor DNA (ctDNA) analysis as a potential measure of response in cHL after CD30 targeted CAR T-cell therapy.

The ASH poster, titled, “Updated Results and Correlative Analysis: Autologous CD30.CAR-T Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial),” reported expanded data from the pilot segment of a Phase 2 trial of autologous CD30.CAR-T in patients with r/r cHL. The CD30.CAR-T cell therapy was demonstrated to be well tolerated with no unexpected safety signals. An ORR of 73.3% and a CR of 60% was observed in 15 heavily pre-treated r/r cHL patients, suggesting strong anti-tumor responses. Additionally, CD30.CAR-T expansion and persistence was observed after CD30.CAR-T infusion.

In an oral podium presentation on December 12, titled, “Ultrasensitive ctDNA Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial),” research examining the potential of ctDNA as a biomarker in r/r cHL after CD30 CAR-T therapy were reported. Foresight Diagnostics’ PhasED-Seq MRD assay was used to measure ctDNA at multiple timepoints throughout therapy. Data showed that ctDNA responses mirrored radiographic responses, suggesting that ctDNA levels could be predictive of patient response to CAR-T therapy. Researchers also determined that PhasED-Seq ctDNA analysis is a viable biomarker to monitor responses and predict outcomes in patients with r/r cHL treated with CD30.CAR-T Cell Therapy.

“The data presented at ASH 2022 continue to demonstrate the CD30.CAR-T cell therapy to be well tolerated with excellent anti-tumor responses in patients with relapsed or refractory classical Hodgkin lymphoma. This includes an overall response rate of 73.3% in heavily pretreated patients, as well as good expansion and persistence after infusion,” stated Sairah Ahmed, M.D., principal investigator, lead presentation author, and Associate Professor, The University of Texas MD Anderson Cancer Center.

“We are pleased to present research demonstrating the potential of minimally invasive ctDNA analysis as a viable method to monitor responses, rapidly risk stratify, and predict outcomes of patients with r/r cHL treated with CD30.CAR-T therapy,” stated David M. Kurtz, M.D., Ph.D., lead presenter and Assistant Professor, Department of Medicine (Oncology), Stanford University.

CD30 is a well validated lymphoma target with homogeneous expression in 98% of cHL and a significant proportion of subsets of non-Hodgkin lymphoma (NHL). TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein.

“We continue to be intrigued by the data being generated from our ongoing Phase 2 CHARIOT trial of TT11, which show the therapy to be safe and well tolerated, along with clear signals of efficacy, in patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma,” said Ivan Horak, M.D., Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics.

TT11 was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) and PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA).

About Tessa Therapeutics

Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s lead clinical asset, TT11, is an autologous CD30-CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b). TT11 has been granted RMAT designation by the FDA and access to the PRIME scheme by European Medicine Agency. Tessa is also advancing an allogeneic “off-the-shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility. For more information on Tessa, visit www.tessacell.com.  

Cautionary Note on Forward Looking Statements

This press release contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, to the fullest extent applicable) including, without limitation, with respect to various regulatory filings or clinical study developments of the Company. You can identify these statements by the fact that they use words such as “anticipate,” “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the Company’s financial results, the ability to raise capital, dependence on strategic partnerships and licensees, the applicability of patents and proprietary technology, the timing for completion of the clinical trials of its product candidates, whether and when, if at all, the Company’s product candidates will receive marketing approval, and competition from other biopharmaceutical companies. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made, and disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company’s products are expressly for investigational use pursuant to a relevant investigational device exemption granted by the U.S. Food & Drug Administration, or equivalent competent body. 

http://mrem.bernama.com/viewsm.php?idm=45001

AGC BIOLOGICS AND GORE COLLABORATE ON NEW PROTEIN A-BASED PURIFICATION TECHNOLOGY AND CONTRACT MANUFACTURING SERVICES FOR ANTIBODY THERAPIES

GORE® Protein Capture Devices and AGC Biologics development and manufacturing platforms help advance downstream purification and support effective development and manufacturing

Seattle, Dec 13 (Bernama-GLOBE NEWSWIRE)
 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the CDMO’s contract development and manufacturing services. 

By using GORE and AGC Biologics, biopharmaceutical companies can improve downstream purification processes through increased productivity of the Protein A step, enabling a full single-use downstream process, which can eliminate column bioburden from storage, reduce manufacturing footprint, and help lower costs for clinical manufacturing and select scale commercial manufacturing.  

The collaboration includes the family of GORE® Protein Capture Devices with Protein A, which improves productivity in Protein A affinity purification, and provides high binding capacity at short residence times, alongside AGC Biologics’ mAb-based CDMO services. The joint offering from Gore and AGC Biologics is available across various sites in the AGC Biologics’ network.  

“This is a notable example of how our technology can support antibody-based therapies coming to market by addressing bottlenecks and boosting productivity” said William Barrett, Ph.D., Product Specialist, for GORE PharmBIO. “Our portfolio of GORE Protein A Capture Devices, with a unique expanded polytetrafluoroethylene (ePTFE) membrane, offers a scalable solution and we are thrilled to work with ACG Biologics so customers can reach their next clinical or commercial milestones.” 

AGC Biologics’ scientists have several decades of R&D experience in the monoclonal antibody space. The company has established more than 200 mammalian and microbial cell culture-based products. AGC Biologics’ historic work in implementing early-on high-throughput titer assessments of monoclonal cell lines helps streamline its early-phase mAb product programs.  

“Investments in new technologies like the GORE Protein Capture Device are important to meet our clients’ needs and address the changes in the monoclonal antibody market,” said Kasper Møller, Chief Technical Officer of AGC Biologics. “We are excited to offer this new technology for GMP manufacturing at relevant scales throughout our manufacturing network.” 

Learn more about GORE Protein Capture Devices with Protein A and get the latest information on upcoming events at www.gore.com/capturemoremAbs. 

To learn more about AGC Biologics’ cell line development services, visit https://www.agcbio.com/capabilities/process-development/cell-line-development.  

Learn more about AGC Biologics’ full line of mammalian-based manufacturing services at https://www.agcbio.com/capabilities/mammalian.  

http://mrem.bernama.com/viewsm.php?idm=44999

ACTYV.AI APPOINTS SANJEEV CHHABRA AS CHIEF GROWTH OFFICER TO DRIVE GLOBAL EXPANSION



KUALA LUMPUR, Dec 13 (Bernama) -- Singapore-headquartered artificial intelligence (AI)-powered enterprise software-as-a-service (SaaS) platform, actyv.ai, has appointed Sanjeev Chhabra as its chief growth officer to drive global expansion.

“Sanjeev brings a strategic mindset and is a business builder known for reliability, integrity and discipline.

“His leadership and experience in driving synergies to deliver exceptional results will accelerate future growth and global expansion of our platform,” founder and global chief executive officer Raghunath Subramanian said in a statement today.

Meanwhile, Chhabra said the appointment is an exciting as well as challenging next step in his career.

“This (appointment) would allow me to build on the significant achievements of actyv.ai in offering technology solutions globally,” he said.

Chhabra is a corporate banker with more than 25 years of experience in client management and credit risk management with extensive international exposure across geographies including South East Asia, Middle East (Gulf Cooperation Council), Africa and India, building and leading teams to drive revenue growth. 

His stints include Standard Chartered Bank (sustainable finance, credit and portfolio management, leveraged finance) across Dubai, UAE, Singapore and India, ING Bank (investment banking) and Bank of America (corporate finance).

Chhabra’s areas of expertise are originating and executing complex transactions across sectors for large corporates, multinationals and private equity funds.

-- BERNAMA

Tuesday, 13 December 2022

AM BEST AFFIRMS CREDIT RATINGS OF CHINA TAIPING INSURANCE (HK)

KUALA LUMPUR, Dec 13 (Bernama) -- AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of China Taiping Insurance (HK) Company Ltd [CTPI(HK)]. 

AM Best said in a statement that the credit ratings (ratings) which have a stable outlook reflect CTPI(HK)’s balance sheet strength, which was assessed as very strong as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management.

“It also incorporates the rating enhancement that CTPI(HK) receives from its parent, China Taiping Insurance Holdings Company Ltd (CTIH),” it said.

The rating agency said, CTPI(HK)’s very strong balance sheet strength is underpinned by its strongest level of risk-adjusted capitalisation as measured by Best’s capital adequacy ratio.

“The company’s capital and surplus (C&S) including minority interests increased by 1.2 per cent to HK$5.09 billion (RM2.90 billion) in 2021, mainly attributed to positive net investment returns. 

“CTPI(HK)’s investment portfolio consists mostly of income-generating assets including investment property, bonds and unlisted fixed rate funds,” it added.

The unlisted fund investments accounted for 28 per cent of the company’s C&S in 2021, representing a high level of asset concentration risk. Following sizable impairment losses recognised in 2020 and 2021, the company liquidated two major unlisted funds with about half of the proceeds booked as receivables. 

Going forward, AM Best expects the company to adopt a prudent investment strategy, and to exercise increased scrutiny in its risk selection, particularly for high-risk illiquid investments.

CTPI(HK) also continued to improve asset quality by lowering its non-investment grade bond holdings over the past few years.

The company is ranked fourth in Hong Kong’s non-life insurance segment in terms of gross premium written in 2021, with a market share of 4.3 per cent. Its product lines consisted mainly of health (A&H), fire, motor and general liability.

-- BERNAMA 

Monday, 12 December 2022

MARY KAY PROTECTS CRITICALLY ENDANGERED LEMURS AND OTHER WILDLIFE IN PARTNERSHIP WITH THE ARBOR DAY FOUNDATION

 


DALLAS, Dec 9 (Bernama-BUSINESS WIRE) -- Today, Mary Kay Inc., a global advocate for corporate sustainability and environmental stewardship, announced the completion of a reforestation project in Madagascar in partnership with the Arbor Day Foundation, Omaha’s Henry Doorly Zoo and Aquarium, and the Madagascar Biodiversity Partnership. The announcement comes as representatives from around the world gather in Montreal at the United Nations Convention on Biological Diversity (COP 15) to tackle the world’s biodiversity crisis. 
 
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005696/en/ 

Sustainable forest management is essential to biodiversity conservation. The 42,000-tree project in Southeast Madagascar focused on reversing decades of forest destruction. The forest is home to critically endangered lemurs and other wildlife species found nowhere else on earth. Tree planting efforts were also intended to improve resiliency for the forest and neighboring communities.

Sunday, 11 December 2022

INDUSTRY COMMITS TO ZERO RESIN LOSS INTO THE ENVIRONMENT

 

From left: Encik Azizin Zainudin, Head (Product Stewardship & Toxicology), Group HSSE, PETRONAS; Encik Alias bin Mamat, Head of Plant, PETRONAS Chemicals LDPE Sdn Bhd; Dr Salmaan Hussain Inayat-Hussain, Head (Environment, Social Performance & Product Stewardship), Group HSSE, PETRONAS; Mr CC Cheah, Vice-President, Malaysian Plastics Manufacturers Association; Encik Shazali Wosnin, Head (Marketing & Sales – Polymer), PETRONAS Chemicals Group; and Encik Mohd Nizam bin Ahmad, Head of Plant, PETRONAS Chemical Ethylene Polyethylene Sdn Bhd launching OCS Malaysia via a palm scanning gimmick.

KERTEH, Dec 9 (Bernama) -- The Malaysian Plastics Manufacturers Association (MPMA) on 8 December 2022 launched the Operation Clean Sweep® (OCS) programme in the country to drive the local plastics industry and its stakeholders towards zero plastics resin loss into the environment.
 
Speaking at the launch event, MPMA Vice President Mr. CC Cheah highlighted the significance of this programme not just locally but globally. “The historic resolution at the United Nations Environment Assembly (UNEA) 5.2 in March 2022 for the development of an internationally legally binding instrument to end plastic pollution demonstrated the commitment globally to ensure that mankind addresses the issue of plastics pollution urgently and effectively. With the OCS programme in place locally, it will further propel Malaysia’s commitment as a nation towards the global common goal of eradicating plastics pollution.”
 
The OCS programme is a product stewardship programme initiated by the American Chemistry Council (ACC) and the Plastics Industry Association (PLASTICS), and is now an international voluntary programme for the global plastics industry to adopt. By signing up for the programme, companies are to commit to the implementation of good housekeeping and containment practices to avoid leakage of plastics resin in the form of either pellets, flakes or powder out of their premises. It is open not only to plastics manufacturers, but also its stakeholders throughout the supply chain, such as raw material producers, recyclers, logistics service providers and more.